Eltrombopag (EPAG)

DRUG2 trials

Sponsors

Abhay Singh, MD MPH, Centro de Atencion e Investigacion Medica

Conditions

Chronic Myelomonocytic LeukemiaHealthyHealthy DonorsMyelodysplastic Syndromes

Phase 2

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

SuspendedNCT06630221

Abhay Singh, MD MPHChronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2025-06-17End: 2030-01-01Target: 25Updated: 2026-06-05

Phase 4

Bioequivalence Study of Revolade® Eltrombopag 50 mg

Active, not recruitingNCT06834451

Centro de Atencion e Investigacion MedicaHealthy, Healthy Donors

Start: 2025-06-01End: 2025-10-30Target: 30Updated: 2025-06-19

Related Papers

A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations

Blood2025-11-03